A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors
Phase Ib/II open label, multicenter study to evaluate the efficacy and safety of AK112 (anti-PD-1 and VEGF bispecific antibody) combined with AK117#AntiCD47 Antibody# in advanced malignant tumors
Advanced Malignant Tumors
DRUG: AK112|DRUG: AK117|DRUG: Carboplatin|DRUG: Cisplatin|DRUG: 5-Fluorouracil
Number of patients with Adverse Events (AEs), Characterization of incidence, severity and abnormal clinically significant laboratory findings of AEs, Up to approximately 2 years|Number of patients experiencing dose-limiting toxicities (DLTs), During the first 3 weeks|Objective Response Rate (ORR), Up to approximately 2 years
Disease control rate (DCR), Up to approximately 2 years|Duration of Response (DOR), Up to approximately 2 years|Time to response (TTR), Up to approximately 2 years|Progression free survival (PFS), Up to approximately 2 years|Overall survival (OS), Up to approximately 2 years
Phase Ib/II open label, multicenter study to evaluate the efficacy and safety of AK112 (anti-PD-1 and VEGF bispecific antibody) combined with AK117#AntiCD47 Antibody# in advanced malignant tumors